Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC grew its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 59.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 124,704 shares of the biopharmaceutical company's stock after purchasing an additional 46,633 shares during the quarter. Intech Investment Management LLC's holdings in Amicus Therapeutics were worth $1,175,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in Amicus Therapeutics during the 3rd quarter worth approximately $55,000. R Squared Ltd acquired a new stake in shares of Amicus Therapeutics in the fourth quarter valued at approximately $79,000. Virtu Financial LLC purchased a new position in shares of Amicus Therapeutics during the third quarter worth approximately $107,000. KBC Group NV increased its holdings in shares of Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after acquiring an additional 3,120 shares during the period. Finally, Stephens Inc. AR purchased a new stake in Amicus Therapeutics in the 4th quarter valued at $101,000.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on FOLD shares. Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Morgan Stanley reaffirmed an "equal weight" rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Finally, Wells Fargo & Company lowered their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.75.

Remove Ads

Amicus Therapeutics Price Performance

Shares of FOLD traded down $0.07 during mid-day trading on Tuesday, hitting $8.62. The company's stock had a trading volume of 3,054,322 shares, compared to its average volume of 2,410,230. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 1-year low of $8.55 and a 1-year high of $12.65. The firm has a market capitalization of $2.65 billion, a P/E ratio of -47.89, a P/E/G ratio of 1.51 and a beta of 0.69. The firm has a 50-day simple moving average of $9.33 and a 200 day simple moving average of $10.01.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.